AMO959

· Novartis Pharmaceuticals

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AMO959, covering 2026-04-23 to 2026-04-23. Get the full timeline:

Most recent: Clinical Trial Update: A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC [Phase 1, Phase 2]

See pricing